CLX vs KROS · P/E 15, rev $7.10B vs rev $32.0K
The Clorox Company (CLX) versus Keros Therapeutics Inc (KROS) — a side-by-side from cached financials, not a winner call.
The Clorox Company (CLX) is a household & personal products company listed on US.
Keros Therapeutics Inc (KROS) is a biotechnology company listed on US.
Latest reported CLX revenue for 2025-06-30 was $7.10B. Net income was $824.0M. CLX currently screens at market cap $10.89B and trailing P/E 14.6.
Latest reported KROS revenue for 2026-06-30 was $32.0K. Net income was -$52.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. KROS currently screens at market cap $208.8M.
CLX currently screens at market cap $10.89B and trailing P/E 14.6. KROS currently screens at market cap $208.8M.
Not investment advice. Open the CLX and KROS stock pages for the full models.
Not investment advice.